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Abstract
Background/Aim. Peripheral blood (PB) is used more fre-
quently as a source of stem cells (SCs) for allogeneic trans-
plantation. However, the influence of cell source on the
clinical outcome of SC transplantation is not yet well estab-
lished. The aim of this study was to compare the results of
PBSC transplantation (PBSCT) with bone marrow trans-
plantation (BMT) on the basis of engraftment, frequency and
severity of immediate (mucositis, acute Graft versus Host
Disease – aGvHD) and delayed (chronic GvHD – cGvHD)
complications, as well as transplant-related mortality (TRM),
transfusion needs, relapses and overall survival (OS). Meth-
ods. We analyzed 158 patients, women/men ratio 64/94
median age 29 (range 9–57), who underwent allogeneic SC
transplantation between 1989 and 2009. All included patients
had diseases as follows: acute myeloid leukemia (AML) – 39,
acute lymphoblastic leukemia (ALL) – 47, chronic myeloid
leukemia (CML) – 32, myelodysplastic syndrome (MDS) –
10, Hodgkin’s lymphoma (HL) – 2, multiple myeloma (MM)
– 3, granulocytic sarcoma (GrSa) – 3, severe aplastic anemia
(sAA) – 22.  The patients underwent transplantations were
divided into two groups: BMT group (74 patients) and
PBSCT group (84 patients). Each recipient had HLA identi-
cal sibling donor. SCs from bone marrow were collected by
multiple aspirations of iliac bone and from PB by one “Large
Volume Leukapheresis” (after recombinant human granulo-
cyte colony stimulating factor, rHuG–CSF) application (5–12
μg/kgbm, 5 days). Conditioning regimens were applied ac-
cording to primary disease, GvHD prophylaxis consisted of
combination of a cyclosporine A and methotrexate. Results.
Engraftment, according to the count of polymorphonuclear
and platelets, were significantly (p <  0.001) faster in the
PBSCT vs BMT group. The needs for transfusion support
were significantly (p < 0.01) higher in the BMT group. Those
patients had more frequently oropharingeal mucositis grade
3/4 (33.3% vs 10.0%, p < 0.05). There were no significant
differences in the incidence of aGvHD and cGvHD be-
tween the two groups. The patients who underwent PBSCT
had more frequently extensive cGvHD in comparison with
the BMT group (29.1% vs 11.29%, p <  0.05). SC source
(SCS) had no significant influence on the TRM
(21.62% vs 23.8%,  p =  0.64) and the incidence of relapses
(21.6% vs 29.7%, p = 0.32). Finally, the patients treated by
BMT had a significantly better OS (logrank 2.33, p < 0.05).
Conclusion. SCs harvesting from PB resulted in improved
cell yield, faster engraftment, as well as in a decrease of im-
mediate transplantation related complications with a reduced
treatment cost. Allogeneic PBSCT were associated with
more frequent extensive cGvHD, while the influence of SCS
in TRM and relapses was not observed. Finally, the long-
term OS was better in the patients treated by BMT. To verify
impact of SC source on transplantation (PBSCT vs BMT)
overall efficacy, more larger randomized clinical studies are
needed.
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Apstrakt
Uvod/Cilj. Periferna krv (PK) se sve češće koristi kao izvor
matičnih ćelija (MĆ) hematopoeze za alogenu transplanta-
ciju. Uprkos višegodišnjem iskustvu, uticaj izvora MĆ na is-
hod transplantacije u lečenju hematoloških maligniteta nije
jasno definisan.  Cilj rada bio je da se uporede rezultati alo-
genih transplantacija MĆ iz PK (TPMĆ) i transplantacija
koštane srži (TKS) prema dinamici prihvatanja kalema, uče-
stalosti i jačini ranih (mukozitis, akutna bolest „kalem protivVolumen 68, Broj 12 VOJNOSANITETSKI PREGLED Strana 1027
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domaćina“, (graft-versus-host disease  – aGvHD) i odloženih
(hronični GvHD – hGvHD) komplikacija procedure, mor-
talitetu uzrokovanom transplantacijom (TRM), potrebi za
transfuzijama, relapsima i ukupnom preživljavanju (OS).
Metode. Analizirano je 158 bolesnika, 64 ženskog, 94 muš-
kog pola, prosečne starosti 29 godina (9–57), sa oboljenjima:
akutna mijeloidna leukemija (AML) – 39, akutna limfoblast-
na leukemija (ALL) – 47, hronična mijeloidna leukemija
(CML) – 32, mijelodisplastični sindrom (MDS) – 10, Hodg-
kinova bolest (MH) – 2, multipli mijelom (MM) – 3, granu-
locitni sarkom (GrSa) – 3, teška aplatična anemija (sAA) –
22, kod kojih je u periodu 1989–2009. urađena alogena tran-
splantacija MĆ. Bolesnici su prema izvoru transplantiranih
MĆ bili podeljeni u dve grupe: prva grupa sa TKS – 74  i
druga sa TPMĆ – 84 bolesnika. Kod svih bolesnika davalac
je bio HLA podudarni srodnik. Matične ćelije iz koštane srži
prikupljene su multiplim aspiracijama bedrene kosti, a iz pe-
riferne krvi jednom „aferezom velikog volumena“ posle
primene rekombinantnog faktora koji stimuliše ljudske ko-
lonije (rHuG–CSF, 5–12 μg/kgtm, 5 dana). Svi bolesnici
primili su neselektovanu suspenziju MĆ. Kondicioni režimi
bili su prilagođeni bolestima, a prevencija GvHD bila je
kombinacija ciklosporina A i metotreksata. Rezultati. Pri-
hvatanje kalema, prema broju polimorfonukleara i trombo-
cita bilo je značajno brže (p < 0,001) u grupi bolesnika sa
TPMĆ, nego u grupi sa TKS. Potrebe za transfuzijama bile
su značajno veće u grupi bolesnika sa TKS (p < 0,01). Ovi
bolesnici imali su češće orofaringealni mukozitis stepena
3/4 (33,3% vs 10,0%, p < 0,05). Nije bilo značajne razlike u
učestalosti aGvHD i hGvHD među grupama. Bolesnici sa
TPMĆ imali su značajno češći hGvHD ekstenzivne forme
(29,1% vs 11,29%, p < 0,05). Izvor MĆ nije bitnije uticao na
TRM (21,62% vs 23,8%, I= 0 ,64) i relapse (21,6% vs 29,7%,
p = 0,32). Bolesnici sa TKS imali su značajno bolje OS (lo-
grank 2,33; p < 0,05).  Zaključak. Periferna krv kao izvor
obezbedila je veći prinos ćelija i brže prihvatanje kalema, sa
ređim ranim komplikacijama transplantacije, što je uticalo na
ekonomski aspekt lečenja. Alogene TPMĆ bile su praćene
češćom pojavom ekstenzivne forme hGvHD, dok uticaj iz-
vora MĆ na TRM i relaps bolesti nije utvrđen. Ukupno pre-
življavanje bilo je bolje kod bolesnika lečenih primenom
TKS, ali za definitivno zaključivanje potrebno je randomizi-
rano ispitivanje većeg broja ispitanika.
Ključne reči:
hematološke neoplazme; lečenje; transplantacija,
homologna; transplantacija hematopoeznih matičnih
ćelija; kostna srž; krv; lečenje, ishod.
Introduction
Allogeneic type of stem cell (SC) transplantation is the
best therapeutic option for the treatment of inherited, and
some acquired diseases of hematopoietic system and various
hematological malignancies. Hematopoietic SC could be
collected either from the bone marrow (BM) which is their
natural residence or from the peripheral blood (PB) after
chemotherapy and/or recombinant hematopoietic growth
factors, as well as from the umbilical blood. Since 1995, PB
has been almost a unique SC source (SCS) within autologous
setting. Knowledge that PB has significantly higher number
of immunocompetent cells, basically T lymphocytes, that
could cause strong „Graft versus Leukemia“ effect and the
fact that the use of recombinant human granulocyte colony
stimulating factor (rHuG–CSF) is harmless for donor 
1, has
led to more frequent use of this particular SCS in transplant
procedures. According to the European Group for Bone Mar-
row and Blood Transplantation (EBMT), from a total num-
ber of allogeneic SCT in 2007, even 75% represents those
with the SCS from the peripheral blood 
2. The results of allo-
geneic PB SC transplantation (PBSCT) were compared with
the allogeneic BM transplantation (BMT) for the treatment
of hematologic malignancies. Allogeneic PBSCT is followed
with faster engraftment as compariset with BMT and there-
fore with a reduced amount of early complications related to
the period of iatrogenic myelosuppression, such as mucositis
and some types of infections 
3–8. There are two different
types of graft versus host disease (GVHD); acute GVHD
(aGVHD) and chronic GVHD (cGVHD). The majority of
authors 
5, 6 have citated that PBSCT is followed with higher
risk of appearance of cGvHD 
5, 6, while reports on the impact
of SCSs on the frequency and severity of aGvHD are contro-
versial 
7, 9–11.
Until nowadays, there has been no consensus between
investigators on the influence of SC source on the disease
relapse, transplant related mortality (TRM) and overall sur-
vival (OS). According to the majority of them, there is no
significant impact of SCS on relapses, TRM and OS 
6, 12.
There are some study groups that emphasize that allogeneic
PBSCT in adults, especially in the cases of advanced stages
of leukemia, has less TRM and better OS in comparison with
allogeneic BMT 
7, 8, 13–15.
The aim of this retrospective study was to compare
PBSCT with BMT considering the engraftment, frequency
and severity of immediate (mucositis, aGvHD) and delayed
(cGvHD) complications, relapses TRM, and OS.
Methods
We analyzed the data on 158 patients, 64 women, 94
men median age 29 years (range 9–57), with different he-
matological diseases: acute myeloid leukemia (AML) – 39,
acute lymphoblastic leukemia (ALL) – 47, chronic myeloid
leukemia (CML) – 32, myelodysplastic syndrome (MDS) –
10, Hodgkin's lymphoma (HL) – 2, multiple myeloma
(MM) – 3, granolocytic sarcoma (GrSa) – 3, severe aplastic
anemia (SAA) – 22) who underwent allogeneic SC trans-
plantation in our center from 1989 till 2009 (20 years of
follow up) (Table 1).
The patients were divided into two groups according to
SC source: in the first group (BMT) the SC source was BM –
74 patients (AML – 17, ALL – 13, CML – 20, MDS – 2,
MM – 1, GrSa – 1, SAA – 20) and in the second group
(PBSCT) SCs which originate in PB – 84 patients (AML –
22, ALL – 34, CML – 12, MDS – 8, HL – 2, MM – 2, GrSa
– 2, SAA–2) (Table 2).Strana 1028 VOJNOSANITETSKI PREGLED Volumen 68, Broj 12
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Table 1
Clinical characteristics of the patients before the stem cell transplantation (n = 158)
Parameter Values
Average age (age range), (years) 29 (9–57)
Women/men ratio (n) 64/94
Diagnosis (n)
     severe aplastic anemia
     chronic myeloid leukemia
        chronic phase
        acceleration/ blast crisis
     Acute myeloid leukemia (n)
        CR1
*
        CR2
**
     Acute lymphoblastic leukemia (n)
        CR1
        CR2
        resistant disease
     Myelodysplastic syndrome (n)
     Hodgkin lymphoma (n)
     Multiple myeloma (n)
     Granulocytic sarcoma (n)
22
32
27
3/2
39
36
3
47
28
11
8
10
2
3
3
Type of donor (n)
     singeneic
     HLA identical sibling
     HLA mismatched
     haploidentical
5
146
5
2
Sources of stem cell (n)
     bone marrow
     peripheral blood
74
84
Conditioning regimen (n)
     busulfan and cyclophosphamide
     cyclophosphamide + antitbymocyte globulin
     other
114
22
22
Graft versus host disease prophylaxis (n)
     cyclosporine A + metotrexate
     other
130
28
*CR1– first complete remission; 
**CR2 – second complete remission
Table 2
Clinical characteristics of 158 patients according to the stem cell source
Group of patients Parameter BMT (n = 74) PBSCT (n = 84)
Average age (age range), (years) 26 (9–52) 28 (13–57)
Diagnosis (n)
     severe aplastic anemia
     chronic myeloid leukemia
     acute myeloid leukemia
     acute lymphoblastic leukemia
     myelodysplastic syndrome
     hodgkin lymphoma
     multiple myeloma
     granulocytic sarcoma
20
20
17
13
2
0
1
1
2
12
22
34
8
2
2
2
BMT – bone marrow transplantation; PBSCT – peripheral blood stem cell transplantation
Each patient had a HLA sibling donor. Five of them
were syngeneic SC transplanted, 146 fully matched, 5 HLA
mismatched and 2 were haploidentical. SCs from the BM
were collected in the standard way, in the conditions of total
anesthesia, by multiple needle aspiration from the donor iliac
crest up to 15 mL/kgbm. SCs from the PB were usually col-
lected, after an with apheresis of “large volume” that fol-
lowed previous mobilization rHuG–CSF, 5–12 µg/kgbm for
5 consecutive days. All the patients received unselected sus-
pension of SCs and in the cases of recipient–donor ABO in-
compatibility, adequate pre-and peritransplant preparation
were performed.
Conditioning regimens were adjusted to the primary
diseases. In the cases of acute leukemias, CML and GrSa
combination of busulfan and cyclophosphamide 2 (Bu–Cy2)
with or without addition of idarubicine (IDA) was given,
whilst in MM Bu–Cy2+Melphalane was given. Conditioning
in SAA was consisted of cyclophosphamide and antithymo-
cyte globulin (Cy+ATG). Most of the used prevention of
GvHD included combination of cyclosporine A and metho-Volumen 68, Broj 12 VOJNOSANITETSKI PREGLED Strana 1029
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trexate (CsA+MTX) – “short” Seattle regimen 
16. In the
posttransplant period, the patients received antimicrobial
prophylaxis against possible infections (viral, fungal, bacte-
rial,  Pneumocystis jiroveci) along with the applications of
intravenous immunoglobulins until the reconstitution of the
immune system. All blood products were irradiated and fil-
trated. Engraftment is defined as the recovery of polymorpho-
nuclears (PMNs) above 0.5  ×  10
9/L and platelets (Plt) over
20 × 10
9/L in three consecutive days. BM analyses were done
on the days +14 and +28 after SC transplantation and chimer-
ism was estimated with the available methods (sex chromo-
some, cytogenetic marker of disease, red blood cells pheno-
type, DNA isolation) starting from day +40 and afterwards in
three months following SC transplantation. Grading of aGvHD
was according to the approved “consensus” criteria 
17. All the
patients who were alive at least 90 days after SC transplanta-
tion with adequate engraftment were enrolled in the analysis
for cGvHD. TRM is defined as death after SC transplantation,
while relapse is not included as a possible cause.
For comparison of the existence of some variables be-
tween the groups the 
2 test was used. The analysis with the
OS were evaluated with Kaplan–Meier method and Mann,
Whitney test, were evaluated. The differences were consid-
ered as statistically significant at p values less than 0.05.
Results
The patients with PBSCT received much better speci-
men (sample) of mononuclear cells (MNC) (10.07  ±  7.31
× 10
8  vs  2.33 ± 0.79 × 10
8,  p <  0.001) in comparison with
BMT. Engraftment, according to the number of PMN
(> 0.5 × 10
9/L) and Plt (>  20  ×  10
9/L) were significantly
faster (p < 0.001) in the group of the patients treated with
PBSCT for 6 days (Table 3). Needs for transfusion support
of blood products (red blood cells – RBC, and Plt) were sig-
nificantly higher in the BMT group (p < 0.01). The patients
with BMT had more frequently oropharingeal mucositis
grade 3–4 (33.33% vs 9.5%, p < 0.05) in comparison with
the other group (Table 3). There were no significant differ-
ence between the two groups according to the incidence of
aGvHD (47.3% vs 45.2%, p =  0.92). The patients with
PBSCT had more often advanced form of aGvHD (3–4) but
not at a significant level (4.05% vs 14.2%, p = 0.055). Al-
though between the compared groups (BMT vs PBSCT)
there were no differences in the incidence of cGvHD (37.1%
vs 49.1%, p = 0.16), extensive form of cGvHD was signifi-
cantly more frequent in the group with SCs originated from
PB (11.29% vs 29.16%, p < 0.05). We did not notice signifi-
cant differences in the incidence of relapses (21.6% vs
29.7%,  p =  0.32) and TRM (21.62% vs 23.8%, p = 0.64)
between  the two groups of patients (Table 3).
The patients with BMT had significantly better OS in
comparison with the other group (log–rank 2.33, p < 0.05,
with median survival (X)  50.72 ± 65.79  months,  p < 0.05)
(Figure 1).
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Fig. 1 – Overall survival in the 158 patients regarding the
stem cell source
BMT – bone marrow transplantation; PBSCT – peripheral blood stem cell
transplantation
Furthermore, among the isolated, homogenous groups
of patients concerning primary disease (AML – totally 39,
BMT– 17, PBSCT – 22), the results were similar (Table 4).
Table 3
Results of stem cell transplantation in all patients according to the number of mononuclear cells (MNC),
polymorphonuclears (PMN), platelet (Plt), needs for red blood cells (RBC) transfusions acute and chronic graft-versus-host
disease (GvHD) and mucositis accurrence, transplant-related mortality (TRM) and relapses
Group of patients Parameter BMT (n = 74) PBSCT (n = 84) p
MNC × 10
8/kg bm 2.33 ± 0.79 10.07 ± 7.31  < 0.001
PMN > 0.5 × 10
9/L (days) 17.19 ± 5.65 11.06 ± 1.92  < 0.001
Plt > 20 × 10
9/L (days) 21.31 ± 5.46 15.35 ± 2.44  < 0.001
RBC transfusions (n) 4.0 (2–16) 2.0 (1–23)  < 0.01
Plt transfusions (n) 3.0 (1–8) 1.0 (0–16)  < 0.01
Mucositis grade 3–4 (%) 33.33 9.5  < 0.05
Acute GvHD (%)
     grade 3–4
47.32
4.05
45.26
14.29
  0.92
 < 0.05
Chronic GvHD (%)
     limited
     extensive
37.16
25.87
11.29
49.16
20.00
29.16
  0.16
  0.92
 < 0.05
TRM (%) 21.62 23.8   0.69
Relapses (%) 21.6 29.7   0.32
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The compared groups (BMT vs. PBSCT) were not dif-
ferent in the incidence of aGvHD (41.17% vs 40.9%,
p =  0.75) and aGvHD grade 3–4 (11.76% vs 27.21%,
p = 0.43). Also, there was no significant difference in the in-
cidence of cGvHD (25% vs 50%, p = 0.23). Extensive form
of cGvHD was more frequent in the group of patients treated
with PBSCT (6.2% vs 40.0%, p < 0.05). According to TRM
and relapses, there were no significant differences between
those two groups of patients (17.6% vs 13, 6%, p = 0.91),
(17.6%  vs 9.1%, p = 0.75), respectively. The patients who
underwent BMT had the better OS than those in the PBSCT
group (log–rank 3.4, p < 0.01) (Figure 2).
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Fig. 2 – Overall survival in the 39 patients with acute
myeloid leukemia regarding the stem cell source
BMT – bone marrow transplantation; PBSCT – peripheral blood stem cell
transplantation
Discussion
Hematopoietic SC, used for the reconstitution of lym-
phohematopoiesis after the myeloablative chemo- or radio-
therapy, could be received from four different sources: BM,
PB, umbilical blood and rarely from the fetal liver. SCSs,
among other, differ in their reconstitution and immunological
characteristics which are determined by their cell structure.
In “steady state” conditions in the circulation there is around
0.06% CD34+ cells, while their number is 18 times higher in
the BM (1.1%) 
18, 19. After the use of recombinant hemato-
poietic growth factors (predominantly rHuG–CSF), SCs
from the extravascular compartment of BM are migrating to
the circulation. Such knowledge is a basis for the use of PB
as a SCS in transplant hematology. A cell structure of unse-
lected suspension of SCs from PB and BM is significantly
different 
19. Following mobilization with addition of rHuG–
CSF allograft that origins from PB consists of 2 to 4 times
higher number of CD34+ cells, even 10 times higher number
of T lymphocytes, monocytes and natural killer (NK) cells
than allograft from BM 
19, 20. Concerning such findings, it is
clear that investigations of many study groups 
3–6, the same
as ours, consider that PBSCT is followed with a significantly
faster engraftment as compared with BMT. Faster engraft-
ment influences on shortening of duration of iatrogenic BM
aplasia and thus in the case of PBSCT, there is a significantly
less need for transfusion support (RBC, Plt) and immediate
complications of procedure are very rare (oropharingeal mu-
cositis). From this point of view, our results are compatible
with the mentioned facts.
As concerning the frequency and severity of aGvHD in
BMT and PBSCT, reports are rather controversial. Initially,
such as the EBMT analysis published, significantly much
frequent appearance of aGvHD in the cases of PBSCT were
registrated 
6, which is due to the activity of a large number of
allogeneic immunocompetent cells that are infused through
this particular procedure. That was showed in addition in the
course of two other meta-analyses 
9, 15. Such findings were
not approved in other studies with no significant difference
in the incidence of aGvHD between those two groups 
5, 11.
Application of rHuG–CSF within the mobilization process,
results in immunomodulatory effect among cells in the allo-
graft suspension, with the majority of suppressive Th2 cyto-
kines and consecutively reduction of aGvHD frequency, de-
spite a large number of infused T lymphocytes 
9.
In our clinical study, similarly to the previous reports,
we noticed no difference in the frequency of aGvHD be-
tween the two compared groups, although the patients with
PBSCT had more commonly advanced forms of aGvHD, but
without a statistical significance.
Considering impact of SCS on the frequency of
cGvHD, the majority of reports emphasized that PBSCT is
followed with higher risk for the development of cGvHD,
especially an extensive form 
5, 6, 9, 11, 15, 21 and we came to the
same conclusion within our group of patients. But, there are
some opposite attitudes, according to which SCS does not
have any significant influence on the severity and frequency
of cGvHD 
22. A complete difference in those two findings
could be caused by various factors, such as: insufficiency of
statistical methods, small number of tested patients, the pres-
Table 4
Results of stem cell transplantation in the homogenous group of 39 patients with acute myeloid leukemia
Group of patients Parameter BMT (n = 17) PBSCT (n = 22) p
Acute GvHD (%)
     grade 3–4
41.17
11.76
40.90
27.2
  0.75
  0.43
Chronic GvHD (%)
     limited
     extensive
25
18.78
6.22
50
10
40
  0.23
  0.38
 < 0.05
TRM (%) 17.6 13.6   0.91
Relapses (%) 17.6 9.1   0.75
BMT – bone marrow transplantation; PBSCT – peripheral blood stem cell transplantation; GvHD – graft versus host disease;
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ence of unhomogenuos groups of patients considering pri-
mary disease, follows-up in less than 100 days after trans-
plant, in vivo immunomodulatory effect of posttransplant use
rHuG–CSF, etc 
23. Also, it should be kept in mind the fact
that usually there is no consensus an the exact diagnosis and
grading of cGvHD.
Recent studies are not unified in defining impact of
SCSs on the incidence of relapses, OS and TRM. The pres-
ence of cGvHD could be, according to theoretical knowl-
edge, followed with potential graft versus leukemia effect
with better control of minimal residual disease and thus
fewer rates of relapses and also better OS. Also, the exis-
tence of extensive form of cGvHD is followed with higher
risk for TRM. Despite the relevant theoretical knowledge,
most studies approved no significant difference in the inci-
dence of relapses, TRM and OS between PBSCT and
BMT 
6, 12, 15, 24. Some reports emphasize that PBSCT is useful
in advanced stages of CML (acceleration and blast crisis)
and acute leukemias, with lower relapses and better
OS 
7, 13, 14, 25. In our investigation, we noticed no significant
difference in the incidence of relapses and TRM considering
SCS, neither in the whole group of patients (N = 158), nor in
the homogenous group with AML. Nevertheless, the patients
who underwent BMT (the whole group and the homogenous
group with AML) had significantly better OS as compared to
the patients who received PBSCT. The fact that the patients
with PBSCT had more frequently, potentially fatal, extensive
form of cGvHD could be the reason for such finding.
The results of this retrospective analysis are in accor-
dance with findings from other studies. PB, as a source of
SC, gives larger harvest of MNC and thus higher number of
hematopoietic progenitor cells that lead to faster engraft-
ment. Faster engraftment is followed by less immediate
complications of the transplant procedure (infection, muco-
sitis) and in that way, economic aspect is better (lower need
for transfusion support and antibiotics, shorter hospitaliza-
tion). The patients who underwent PBSCT more frequently
had extensive, potentially fatal, form of cGvHD having bad
impact on their quality of life. There was no difference in the
frequency of aGvHD, incidence of relapses and TRM be-
tween the two groups concerning SCS. OS was better in the
group with BMT due to a potentially fatal outcome of the
cGvHD in PBSCT setting.
Conclusion
The data obtained in this clinical study show that the
cell yield is higher in PB harvest, that engraftment is faster,
with decreased immediate transplantation-related complica-
tions in PBSCT setting. For the advanced stage of acute leu-
kemias and accelerated CML or CML with blast crisis, as
well as in the ABO incompatible transplantations or a sig-
nificant difference in donor vs recipient body mass, PB is a
more sufficient SCS. However, allogeneic PBSCT is associ-
ated with more frequent extensive cGvHD, but without in-
fluence on the TRM and relapses. On the contrary, BM is
superior for SAA and chronic phase of CML. To confirm the
influence of SCS on the overall treatment efficacy (PBSCT
vs BMT), more larger randomized clinical studies are
needed.
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